MarketCap
Facebook
X
Telegram
Alnylam Pharmaceuticals Net Income | ALNY
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 314 M | -278 M | -440 M | -1.13 B | -853 M | -858 M | -886 M | -761 M | -491 M | -410 M | -290 M | -360 M | -89.2 M | -106 M | -57.6 M | -43.5 M | -47.6 M | -26.2 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 314 M | -1.13 B | -379 M |
Quarterly Net Income Alnylam Pharmaceuticals
| 2026-Q2 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 164 M | 251 M | -66.3 M | -57.5 M | - | -112 M | -16.9 M | -65.9 M | - | 148 M | -276 M | -174 M | - | -406 M | -277 M | -240 M | - | -205 M | -190 M | -200 M | -244 M | -253 M | -179 M | -182 M | -276 M | -209 M | -219 M | -182 M | -211 M | -245 M | -164 M | -141 M | -142 M | -123 M | -118 M | -107 M | -113 M | -104 M | -90.1 M | -103 M | -90.7 M | -76.8 M | -71.8 M | -50.8 M | -21.4 M | -44 M | -44.1 M | -251 M | -32.4 M | -29.7 M | -18.2 M | -9.01 M | -62.2 M | -19.5 M | -13 M | -11.4 M | -14.3 M | -13.2 M | -13.8 M | -16.3 M | -9.63 M | -14.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 251 M | -406 M | -104 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
-525 M | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
-64.9 M | $ 5.64 | 5.92 % | $ 691 M |  USA |
 |
Akebia Therapeutics
AKBA
|
-5.3 M | $ 0.99 | 4.33 % | $ 255 M | USA |
 |
Alector
ALEC
|
-143 M | $ 2.19 | 2.1 % | $ 226 M | USA |
 |
Aligos Therapeutics
ALGS
|
-24.2 M | $ 5.08 | 0.96 % | $ 50.2 M | USA |
 |
Alkermes plc
ALKS
|
242 M | $ 45.83 | 0.22 % | $ 7.55 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
-191 M | $ 1.79 | 0.28 % | $ 395 M | USA |
 |
Altimmune
ALT
|
-88.1 M | $ 3.31 | 1.22 % | $ 292 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-102 M | $ 1.93 | 0.52 % | $ 104 M | USA |
 |
Amgen
AMGN
|
7.71 B | $ 380.17 | 0.75 % | $ 205 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
98.1 M | $ 23.96 | 0.74 % | $ 1.12 B | USA |
 |
Amarin Corporation plc
AMRN
|
-38.8 M | $ 14.02 | 1.59 % | $ 5.82 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
72.1 M | $ 17.23 | 1.29 % | $ 5.4 B | USA |
 |
AbbVie
ABBV
|
1.82 B | $ 261.94 | 1.87 % | $ 463 B | USA |
 |
AnaptysBio
ANAB
|
-13.2 M | $ 54.77 | 1.67 % | $ 1.58 B | USA |
 |
Anika Therapeutics
ANIK
|
-10.9 M | $ 21.22 | 1.7 % | $ 304 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
78 M | $ 70.92 | 1.04 % | $ 1.42 B | USA |
 |
Aprea Therapeutics
APRE
|
-12.6 M | $ 0.76 | 2.03 % | $ 4.97 M | USA |
 |
Aptevo Therapeutics
APVO
|
-26 M | $ 1.87 | 2.75 % | $ 590 K | USA |
 |
AbCellera Biologics
ABCL
|
-146 M | $ 11.04 | 1.38 % | $ 3.3 B |  Canada |
 |
Aquestive Therapeutics
AQST
|
-83.8 M | $ 4.89 | 2.41 % | $ 523 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-65.8 M | $ 15.23 | 3.39 % | $ 417 M |  Israel |
 |
Ardelyx
ARDX
|
-62 M | $ 3.54 | 0.14 % | $ 853 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
-174 M | $ 5.3 | 1.84 % | $ 192 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 24.35 | 1.95 % | $ 3.1 B | USA |
 |
Artelo Biosciences
ARTL
|
-12.9 M | $ 5.15 | 1.1 % | $ 974 K | USA |
 |
Arvinas
ARVN
|
-81 M | $ 8.44 | 0.41 % | $ 598 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 M | $ 80.24 | 0.11 % | $ 10.7 B | USA |
 |
Assembly Biosciences
ASMB
|
-6.12 M | $ 28.86 | 0.64 % | $ 324 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-33.9 M | $ 1.25 | 6.87 % | $ 39 M | USA |
 |
Atara Biotherapeutics
ATRA
|
32.7 M | $ 9.49 | 1.17 % | $ 119 M | USA |
 |
Agenus
AGEN
|
-3.08 M | $ 7.12 | 2.59 % | $ 212 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
287 M | $ 16.3 | 1.26 % | $ 2.19 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-288 M | $ 1.94 | 2.93 % | $ 516 M |  Britain |
 |
Atea Pharmaceuticals
AVIR
|
-158 M | $ 5.34 | 0.47 % | $ 435 M | USA |
 |
Axon Enterprise
AXON
|
125 M | $ 491.2 | 2.47 % | $ 38.4 B | USA |
 |
Axsome Therapeutics
AXSM
|
-183 M | $ 216.73 | 0.75 % | $ 10.8 B | USA |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.0 | 0.5 % | $ 12.6 M | USA |
 |
BridgeBio Pharma
BBIO
|
-733 M | $ 72.33 | 0.1 % | $ 13.9 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
264 M | $ 8.2 | 0.92 % | $ 1.72 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
-219 M | $ 3.87 | 0.13 % | $ 268 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
22.4 B | $ 2.03 | 2.52 % | $ 115 M | USA |
 |
Beam Therapeutics
BEAM
|
-80 M | $ 24.35 | 1.5 % | $ 2.41 B | USA |
 |
Biogen
BIIB
|
1.29 B | $ 217.62 | 0.22 % | $ 31.9 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-2.03 M | $ 2.48 | 0.2 % | $ 6.11 B | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
349 M | $ 66.22 | 0.82 % | $ 12.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
7.05 B | $ 64.03 | 0.61 % | $ 130 B | USA |
 |
Benitec Biopharma
BNTC
|
-8.8 M | $ 12.11 | 0.08 % | $ 498 M | USA |
 |
Burford Capital Limited
BUR
|
62.6 M | $ 4.35 | 1.13 % | $ 953 M | Britain |